Mesothelioma diagnosis and monitoring rely heavily on imaging. CT scans, MRI, and PET scans each have specific roles. Knowing what each test does, when it is ordered, and what the radiologist is looking for helps you understand your care.
This guide explains mesothelioma imaging tests in plain language. You will learn how CT, MRI, and PET differ, when each is used, what preparation is required, and how they fit into the larger picture of staging and monitoring.
CT Scan: The Foundation
The CT scan, also called a computed tomography scan, is the first and most frequent imaging study in mesothelioma. CT uses X-rays from multiple angles, processed by a computer into cross-sectional images of the chest. The scan shows pleural thickening, pleural effusion, lung involvement, mediastinal lymph nodes, and chest wall invasion in fine anatomical detail.
A chest CT with contrast is the standard for mesothelioma. The contrast is an iodine-based dye injected through a vein during the scan. The dye enhances vascular structures and tumour, making them stand out from normal tissue. Patients with kidney problems or contrast allergies use modified protocols. The scan itself takes a few minutes; the entire appointment is typically thirty to sixty minutes.
CT is used for initial diagnosis, staging, surgical planning, response assessment during treatment, and surveillance after treatment. Typical surveillance schedules involve CT every three to four months for the first year or two, with longer intervals thereafter if the disease is stable.
MRI: When CT Is Not Enough
MRI uses magnetic fields and radio waves rather than X-rays. The images excel at distinguishing soft tissue types, including the boundary between tumour and normal structures like the diaphragm muscle, the heart, and the chest wall. For surgical planning, MRI sometimes adds detail that CT alone cannot provide.
MRI is particularly useful when CT is ambiguous about whether tumour has invaded specific structures. Diaphragm involvement, mediastinal invasion, and chest wall infiltration can sometimes be better assessed with MRI. The cost and longer scanning time mean MRI is reserved for situations where the additional detail will change management.
PET-CT: Metabolic Information
PET-CT combines a CT scan with a metabolic imaging study using a radioactive sugar called FDG. Cancer cells take up the FDG more avidly than normal cells because they consume more energy. The PET image highlights areas of high metabolic activity, which usually correspond to active tumour.
For mesothelioma, PET-CT is used most often for initial staging to assess for distant metastases that might not be visible on CT alone. PET helps detect lymph node involvement, contralateral chest disease, and unsuspected sites elsewhere in the body. PET findings often prompt additional biopsy to confirm metastatic disease before changing treatment plans.
PET-CT is also used during treatment to assess response. Tumours that are responding to therapy show decreased FDG uptake. Tumours that are progressing show increasing uptake. The metabolic information complements the anatomical information from CT and helps distinguish active tumour from post-treatment scarring or fibrosis.
What Preparation Is Required
CT with contrast requires fasting for several hours before the scan and adequate hydration before and after. If you have kidney problems, your doctor may order a creatinine blood test before the scan to verify it is safe to receive contrast. Metformin diabetes medication is sometimes held before and after contrast administration.
MRI requires removal of all metal objects, including jewellery and clothing with metal fasteners. Patients with pacemakers, certain stents, or other implanted metal devices may not be eligible for MRI. The scan involves lying still in a tube for thirty to sixty minutes. Patients with claustrophobia can request a mild sedative.
PET-CT requires fasting for four to six hours before the scan because food affects sugar uptake by the radioactive tracer. After receiving the FDG injection, you wait quietly for about an hour while the tracer distributes through the body. The scan itself takes approximately thirty minutes.
Reading the Reports
Imaging reports follow a standard format. The radiologist describes the findings region by region: pleura, lungs, mediastinum, chest wall, upper abdomen. They note the size and characteristics of any tumour, comparing to prior studies when available. They give an impression summarising the key findings.
Common terms in mesothelioma reports include rind-like pleural thickening, nodular pleural enhancement, pleural effusion, septations, fissural extension, mediastinal lymphadenopathy, and trans-diaphragmatic extension. Ask your oncologist to walk you through the report at your next visit. Understanding what the radiologist saw helps you understand the treatment recommendations that follow.
Imaging During Treatment
Imaging during treatment monitors response. The standard interval for CT during chemotherapy is every two to three cycles, typically every six to nine weeks. The CT looks for change in pleural thickening, change in effusion size, and any new sites of disease. The findings inform whether to continue, modify, or change the treatment.
After completion of curative-intent treatment, surveillance imaging continues every three to four months for the first two years, then every six months for several more years. Most recurrences are detected on imaging before symptoms develop, which sometimes allows earlier treatment of progression.
A Closing Note
Imaging is a constant companion through mesothelioma treatment. Each scan can produce anxiety while waiting for results. The waiting is hard but unavoidable. Most patients develop a routine of scan, follow-up appointment, decision, repeat. The information from each scan informs the next phase.
Ask your oncologist what they are looking for at each scan and what specific findings would change the treatment plan. The answers help you understand which aspects of the report matter most and which are routine. The knowledge replaces some of the uncertainty with clarity.
This article is for educational purposes and does not replace personalised guidance from a treating oncologist or radiologist.